Core Viewpoint - The company reported a 15% year-on-year increase in revenue for Q3 2025, driven by high-margin businesses such as its proprietary brands and primary push business, which saw transaction volumes grow by 120% and over 350% respectively in October [1][2]. Group 1: Company Performance - The rapid growth in performance is attributed to the company's "upward" strategy, focusing on enhancing supply chain capabilities and optimizing product structure [2]. - The proprietary brand business has significantly contributed to the company's profitability, with a notable increase in customer loyalty and repurchase rates due to high-quality, cost-effective products [2]. - The overall revenue growth in Q3 2025 is notably higher than the growth rate observed in the first half of 2025 compared to the first half of 2024, indicating strong performance despite industry challenges [1]. Group 2: Industry Context - The domestic pharmaceutical retail industry is undergoing a deep adjustment and transformation, facing challenges such as rising compliance costs and accelerated market clearing [1]. - The fourth quarter is traditionally a peak sales season for pharmaceuticals, with expectations that companies will exceed previous conservative performance forecasts due to increased flu activity compared to the previous year [3]. - The company's sales of flu-related medications increased by 36% year-on-year in October, with proprietary brand "Le Yaoshi" cold medications seeing a growth of over 135% [3].